tirzepatide patent expiration eli lilly FDA approves Lilly's for weight loss https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and

NEJM Full Text Jastreboff, A.M., et al

Sources: Mayo Clinic: Semaglutide (Subcutaneous Route) Wegovy: Starting Wegovy Pill Diabetes Care: Gradual Titration of Semaglutide Results in Better Tolerability Ozempic: Dosing Information Wharton S, Freitas P, Hjelmesaeth J, et al

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) New England Journal of Medicine In 3,297 patients with T2D, semaglutide reduced major adverse cardiovascular events by 26% versus placebo over 2.1 years (HR 0.74), driven by 39% stroke reduction and 26% nonfatal MI reduction

Two products, Enso Supergreens and A